- search hit 1 of 1
CD40L mediated alternative NF kappa B-signaling induces resistance to BCR-inhibitors in patients with mantle cell lymphoma
Please always quote using this URN: urn:nbn:de:bvb:20-opus-225027
- Drug resistance is a significant obstacle in cancer treatment and therefore a frequent subject of research. Developed or primary resistance limits the treatment success of inhibitors of the B cell receptor (BCR) pathway in mantle cell lymphoma (MCL) patients. Recent research has highlighted the role of the nuclear factor-kappa B (NF kappa B) pathway in the context of resistance to BCR inhibitors in MCL. In this study, we analyzed the dependency of MCL cell lines on NF kappa B signaling and illustrated the ability of CD40L to activate theDrug resistance is a significant obstacle in cancer treatment and therefore a frequent subject of research. Developed or primary resistance limits the treatment success of inhibitors of the B cell receptor (BCR) pathway in mantle cell lymphoma (MCL) patients. Recent research has highlighted the role of the nuclear factor-kappa B (NF kappa B) pathway in the context of resistance to BCR inhibitors in MCL. In this study, we analyzed the dependency of MCL cell lines on NF kappa B signaling and illustrated the ability of CD40L to activate the alternative NF kappa B pathway in MCL. This activation leads to independency of classical NF kappa B signaling and results in resistance to BCR inhibitors. Therefore, ligands (such as CD40L) and their activation of the alternative NF kappa B pathway have a major impact on the drug response in MCL. Furthermore, this study indicates a protective role for cells expressing specific ligands as microenvironmental niches for MCL cells and underlines the significance of therapeutically targeting alternative NF kappa B signaling in MCL.…
Author: | Hilka Rauert-Wunderlich, Ingolf Berberich, Andreas Rosenwald, Martina Rudelius |
---|---|
URN: | urn:nbn:de:bvb:20-opus-225027 |
Document Type: | Journal article |
Faculties: | Medizinische Fakultät / Pathologisches Institut |
Medizinische Fakultät / Institut für Virologie und Immunbiologie | |
Language: | English |
Parent Title (English): | Cell Death & Disease |
Year of Completion: | 2018 |
Issue: | 9 |
Pagenumber: | 86, 1-9 |
Source: | Cell Death and Disease (2018) 9:86 |
DOI: | https://doi.org/10.1038/s41419-017-0157-6 |
Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Tag: | Activation; Bruton Tyrosine Kinase; Ibrutinib; Ligand; Malignancies; PCI-32765; Pathway; Proliferation; Targeted Therapies; Tumor Microenvironment |
Release Date: | 2021/10/08 |
Licence (German): | CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International |